Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Arcutis biotherapeutics, inc. save search
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Published: 2022-06-06 (Crawled : 12:20) - biospace.com/
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 4.65%
H: 1.24%
C: -4.42%
topline dermatitis trial positive results phase 3
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
Published: 2022-03-25 (Crawled : 12:00) - globenewswire.com
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: -0.62%
H: 2.87%
C: -2.22%
trials psoriasis phase 3 plague
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
Published: 2022-02-01 (Crawled : 13:00) - arcutis.com
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 0.8%
H: 4.53%
C: 2.51%
als dermatitis trial phase 3 enroll
Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
Published: 2021-08-25 (Crawled : 14:00) - biospace.com/
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 0.05%
H: 3.88%
C: 1.31%
treatment potential phase 3 trial psoriasis enroll
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
Published: 2021-07-12 (Crawled : 12:15) - globenewswire.com
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 4.75%
H: 2.8%
C: 2.31%
treatment potential dermatitis phase 3 trial enroll
Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021
Published: 2021-05-06 (Crawled : 14:00) - biospace.com/
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 3.5%
H: 0.0%
C: -6.12%
phase 3 iot trial psoriasis symposium plague
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
Published: 2021-05-03 (Crawled : 21:00) - biospace.com/
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 5.31%
H: 0.6%
C: -1.5%
europe phase 3 symposium
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
Published: 2021-04-12 (Crawled : 13:15) - globenewswire.com
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 0.04%
H: 3.83%
C: 1.76%
treatment potential dermatitis phase 3 trial atopic dermatitis
Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis
Published: 2021-01-20 (Crawled : 14:03) - globenewswire.com
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 0.77%
H: 1.28%
C: -2.52%
dermatitis phase 3 treatment
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
Published: 2021-01-13 (Crawled : 14:01) - globenewswire.com
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: -0.92%
H: 4.67%
C: 0.26%
dermatitis phase 3 trial treatment potential atopic dermatitis
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Published: 2020-12-07 (Crawled : 14:01) - globenewswire.com
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 0.88%
H: 2.25%
C: 1.03%
phase 3 trial potential psoriasis plague
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.